| 1. |
- Nyström, Max, et al.
(författare)
-
Secretory leukocyte protease inhibitor in punch biopsies from human colonic mucosa
- 2001
-
Ingår i: Mediators of Inflammation. - : Hindawi Limited. - 0962-9351 .- 1466-1861. ; 10:5, s. 269-272
-
Tidskriftsartikel (refereegranskat)abstract
- Secretory leukocyte protease inhibitor (SLPI) is a well-known protease inhibitor. Its function is thought to be protease/protease-inhibitor balance. Free proteolytic activity, mainly pancreatic elastase, anionic trypsin and granulocytic elastase, has been demonstrated in faecal extracts from patients with ulcerative colitis. We wanted to verify that SLPI is actually secreted from normal human colonic mucosa. Also, we wanted to ascertain whether studies of SLPI secretion based on punch biopsies were dependent on biopsy area or on biopsy circumference. Normal colonic mucosa was sampled during surgery for colonic cancer. A total of 36 samples from four patients were used. Mucosa preparation was carried out using a punch biopsy technique, and samples of 3, 4 and 6 mm diameter were used. All media contained SLPI at varying concentrations. When expressed in terms of the sample area, the secretion per millimetre-squared seemed to decrease with increasing area. When calculated as secretion per circumference, secretion seemed to be constant. In conclusion, SLPI was secreted from normal human colonic mucosa. The SLPI secretion seemed dependent on the circumference of the biopsy rather than on the area of the biopsy.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Persson, Carina Ulla, 1970, et al.
(författare)
-
Measurement properties of the Swedish modified version of the Postural Assessment Scale for Stroke Patients (SwePASS) using Rasch analysis.
- 2017
-
Ingår i: European journal of physical and rehabilitation medicine. - : Edizioni Minerva Medica S.p.A.. - 1973-9095 .- 1973-9087. ; 53:6, s. 848-55
-
Tidskriftsartikel (refereegranskat)abstract
- A previous small-sample (n=150) Rasch analysis of the Swedish modified version of the Postural Assessment Scale for Stroke Patients (SwePASS) suggested problems regarding response categories and redundant items that need confirmation in larger samples with more severe strokes.To evaluate the measurement properties of the SwePASS in patients with acute stroke.A multicentre, cross-sectional study.Two stroke units in Western Sweden.The study cohort included 250 consecutive inpatients undergoing rehabilitation after acute stroke.The SwePASS assessments were performed once within the first four days after admission to the stroke units. The data were analysed according to the Rasch measurement model regarding targeting, model fit, reliability, response category function, local dependence and differential item functioning.Postural control of 250 patients (median age, 76.5 years) was assessed with the SwePASS within median of two days after admission to the stroke units. The SwePASS covered a continuum of different levels of postural control, but had suboptimal targeting with insufficient representation of lower and higher levels of postural control. The reliability was high, the item fit statistics were generally acceptable and there was no differential item functioning by sex, age and stroke localization. However, response categories did not function as expected for four of the 12 SwePASS items and five items exhibited local dependency.The SwePASS exhibited several promising measurement properties. To improve the scale, poor targeting, illogical response categories and local dependency should be addressed.The SwePASS provides valuable clinical information regarding postural control in the acute phase after stroke.
|
|
| 5. |
- Svensson, Åke, et al.
(författare)
-
Rheumatoid arthritis, gold therapy, contact allergy and blood cytokines.
- 2002
-
Ingår i: BMC Dermatology. - : Springer Science and Business Media LLC. - 1471-5945. ; 2:1
-
Tidskriftsartikel (refereegranskat)abstract
- Objective To study the clinical and biochemical effects of a low starting dose for gold therapy in rheumatoid arthritis patients with a contact allergy to gold. Methods Serum cytokines were assayed before and 24 h after the first injection of gold sodium thiomalate (GSTM). Results Contact allergy to gold was found in 4 of 19 patients. Compared to gold-negative patients (starting dose: 10 mg GSTM), there was a larger increase in serum TNFalpha (p < 0.05), sTNF-R1 (NS), and IL-1 ra (p < 0.05) in gold-allergic patients. Conclusions Cytokines are released in blood by GSTM in RA patients with gold allergy. To minimize the risk of acute adverse reactions the starting dose of GSTM should be lowered to 5 mg. Alternatively, patients should be patch-tested before gold therapy; in test-positive cases, 5 mg is recommended as the first dose.
|
|
